<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-10-20">October 20, 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Philipp</forename><surname>Harter</surname></persName>
							<email>p.harter@gmx.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Gynecology &amp; Gynecologic Oncology</orgName>
								<orgName type="institution">Kliniken Essen-Mitte</orgName>
								<address>
									<settlement>Essen, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Hauke</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Center for Hereditary Breast and Ovarian Cancer</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Center for Integrated Oncology (CIO)</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Florian</forename><surname>Heitz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Gynecology &amp; Gynecologic Oncology</orgName>
								<orgName type="institution">Kliniken Essen-Mitte</orgName>
								<address>
									<settlement>Essen, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Reuss</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Coordinating Center for Clinical Trials</orgName>
								<orgName type="institution">Philipps-University of Marburg</orgName>
								<address>
									<settlement>Marburg, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Kommoss</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Women&apos;s Health</orgName>
								<orgName type="institution">Tu ¨bingen University Hospital</orgName>
								<address>
									<addrLine>Tu ¨bingen</addrLine>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frederik</forename><surname>Marme</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">National Center for Tumor Disease/ Department of Gynecology</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andre</forename><surname>´heimbach</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">University of Bonn</orgName>
								<address>
									<settlement>Bonn, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katharina</forename><surname>Prieske</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Gynecology and Gynecologic Oncology</orgName>
								<orgName type="institution">University Medical Center Hamburg-Eppendorf</orgName>
								<address>
									<settlement>Hamburg, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lisa</forename><surname>Richters</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Center for Hereditary Breast and Ovarian Cancer</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Center for Integrated Oncology (CIO)</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Burges</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">University Hospital Munich-Großhadern. Munich</orgName>
								<address>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Guido</forename><surname>Neidhardt</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Center for Hereditary Breast and Ovarian Cancer</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Center for Integrated Oncology (CIO)</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nikolaus</forename><surname>De Gregorio</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">University of Ulm</orgName>
								<address>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ahmed</forename><surname>El-Balat</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">University of Frankfurt</orgName>
								<address>
									<addrLine>12 Onkologisches Therapiezentrum</addrLine>
									<settlement>Frankfurt, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">Krankenhaus Jerusalem</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Felix</forename><surname>Hilpert</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">University of Kiel</orgName>
								<address>
									<settlement>Kiel, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Werner</forename><surname>Meier</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Gynecology</orgName>
								<address>
									<addrLine>Evangelisches Krankenhaus</addrLine>
									<settlement>Duesseldorf, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rainer</forename><surname>Kimmig</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">University of Essen</orgName>
								<address>
									<settlement>Essen, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karin</forename><surname>Kast</surname></persName>
							<affiliation key="aff16">
								<orgName type="department" key="dep1">Department of Gynecology and Obstetrics</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universita ¨t Dresden</orgName>
								<address>
									<settlement>Dresden, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="institution">National Center for Tumor Diseases (NCT)</orgName>
								<address>
									<addrLine>Partner Site Dresden</addrLine>
									<settlement>Dresden, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department">Dresden and German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jalid</forename><surname>Sehouli</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Department of Gynecology and Gynecological Oncology</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Charite ´, Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Klaus</forename><surname>Baumann</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">Klinikum Ludwigshafen</orgName>
								<address>
									<settlement>Ludwigshafen, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Department of Gynecology</orgName>
								<orgName type="department" key="dep2">Gynecologic Endocrinology &amp; Oncology</orgName>
								<orgName type="institution">Philipps-University Marburg</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Jackisch</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<address>
									<addrLine>Sana Klinikum</addrLine>
									<settlement>Offenbach, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tjoung-Won</forename><surname>Park-Simon</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">Medizinische Hochschule Hannover</orgName>
								<address>
									<settlement>Hannover, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lars</forename><surname>Hanker</surname></persName>
							<affiliation key="aff24">
								<orgName type="department">Department of Gynecology &amp; Obstetrics</orgName>
								<orgName type="institution">University Hospital Schleswig-Holstein</orgName>
								<address>
									<addrLine>Campus Lu ¨beck, Lu ¨beck</addrLine>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>Kro ¨ber</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Center for Hereditary Breast and Ovarian Cancer</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Center for Integrated Oncology (CIO)</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jacobus</forename><surname>Pfisterer</surname></persName>
							<affiliation key="aff25">
								<orgName type="department">Center of Gynecological Oncology</orgName>
								<address>
									<settlement>Kiel, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Heidrun</forename><surname>Gevensleben</surname></persName>
							<affiliation key="aff26">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Bonn</orgName>
								<address>
									<settlement>Bonn, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Schnelzer</surname></persName>
							<affiliation key="aff27">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="laboratory">Klinikum rechts der Isar</orgName>
								<orgName type="institution">Technical University of Munich</orgName>
								<address>
									<settlement>Munich, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dimo</forename><surname>Dietrich</surname></persName>
							<affiliation key="aff28">
								<orgName type="department">Department of Otolaryngology, Head and Neck Surgery</orgName>
								<orgName type="institution">University Hospital Bonn</orgName>
								<address>
									<settlement>Bonn, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tanja</forename><surname>Neunho</surname></persName>
							<affiliation key="aff29">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">Dr. Horst-Schmidt-Kliniken</orgName>
								<address>
									<settlement>Wiesbaden, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mathias</forename><surname>Krockenberger</surname></persName>
							<affiliation key="aff30">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">University of Wu ¨rzburg</orgName>
								<address>
									<addrLine>Wu ¨rzburg</addrLine>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sara</forename><forename type="middle">Y</forename><surname>Brucker</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Women&apos;s Health</orgName>
								<orgName type="institution">Tu ¨bingen University Hospital</orgName>
								<address>
									<addrLine>Tu ¨bingen</addrLine>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Nu ¨rnberg</surname></persName>
							<affiliation key="aff31">
								<orgName type="department">Center for Molecular Medicine Cologne (CMMC)</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<settlement>Cologne, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff32">
								<orgName type="department">Cologne Center for Genomics (CCG)</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<settlement>Cologne, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff33">
								<orgName type="laboratory">Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD)</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<settlement>Cologne, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Holger</forename><surname>Thiele</surname></persName>
							<affiliation key="aff32">
								<orgName type="department">Cologne Center for Genomics (CCG)</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<settlement>Cologne, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Janine</forename><surname>Altmu ¨ller</surname></persName>
							<affiliation key="aff31">
								<orgName type="department">Center for Molecular Medicine Cologne (CMMC)</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<settlement>Cologne, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff32">
								<orgName type="department">Cologne Center for Genomics (CCG)</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<settlement>Cologne, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Josefin</forename><surname>Lamla</surname></persName>
							<affiliation key="aff34">
								<orgName type="laboratory">AGO Study Group</orgName>
								<address>
									<settlement>Wiesbaden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>No</roleName><forename type="first">Gabriele</forename><surname>Elser</surname></persName>
							<email>gelser@ago-ovar.de</email>
							<affiliation key="aff34">
								<orgName type="laboratory">AGO Study Group</orgName>
								<address>
									<settlement>Wiesbaden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Du Bois</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Gynecology &amp; Gynecologic Oncology</orgName>
								<orgName type="institution">Kliniken Essen-Mitte</orgName>
								<address>
									<settlement>Essen, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><surname>Hahnen</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Center for Hereditary Breast and Ovarian Cancer</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Center for Integrated Oncology (CIO)</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rita</forename><surname>Schmutzler</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Center for Hereditary Breast and Ovarian Cancer</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Center for Integrated Oncology (CIO)</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Inst</forename><forename type="middle">) Jan</forename><surname>Hauke</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andre</forename><surname>Heimbach</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>Kroeber</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Nu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Janine</forename><surname>Altmu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Heidrun</forename><surname>Pfisterer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Gevensleben</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dimo</forename><surname>Schnelzer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tanja</forename><surname>Dietrich</surname></persName>
						</author>
						<author>
							<persName><surname>Neunho</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Du</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andre</forename><surname>´heim- Bach</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>Kro</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tanja</forename><surname>Neun- Ho ¨ffer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Janine</forename><surname>Alt- Mu ¨ller</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Nu ¨rn- Berg</surname></persName>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">University of Kiel</orgName>
								<address>
									<settlement>Kiel, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff35">
								<orgName type="institution" key="instit1">BRCA1</orgName>
								<orgName type="institution" key="instit2">PTEN</orgName>
								<address>
									<postCode>BRCA2, CDH1, CHEK2, MLH1, MSH2, MSH6, PMS2, PALB2, RAD51C, RAD51D, STK11, TP53</postCode>
									<region>NBN</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff36">
								<orgName type="department">Relationships to Disclose</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-10-20">October 20, 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">9C6D6BFE9C461EEF959DEEB79422C525</idno>
					<idno type="DOI">10.1371/journal.pone.0186043</idno>
					<note type="submission">Received: June 9, 2017 Accepted: September 22, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).</s><s>PLoS ONE 12(10): e0186043.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Ovarian cancer is the leading cause of death of all gynecologic cancers both in the European Union and the United States <ref type="bibr" target="#b0">[1]</ref>.</s><s>In the US, 22,280 patients were diagnosed in 2016 for ovarian cancer and 14,240 died <ref type="bibr" target="#b1">[2]</ref>.</s><s>Despite improvements in chemotherapy <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5]</ref> and surgery <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref> still most patients relapse and finally die of disease.</s><s>A decade ago, it was estimated that about 10-15% of all patients have a hereditary risk for ovarian cancer <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>.</s><s>The first identified predisposition genes were BRCA1 and BRCA2 with a lifetime penetrance regarding ovarian cancer of 35-59% (BRCA1) and 11-17% (BRCA2), respectively <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b12">13]</ref>.</s><s>Unfortunately, several trials which tried to establish a successful screening for ovarian cancer failed <ref type="bibr" target="#b13">[14]</ref>.</s><s>The development of a serous tubal intraepithelial carcinoma (STIC) as a precursor lesion in the fallopian tube with the potential to metastasize within the peritoneal cavity before a solid tumor in the pelvis can be detected, might be one reason for the trial failures <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16]</ref>.</s><s>Consequently, the majority of patients is diagnosed at an advanced stage with the above-mentioned mortality.</s><s>So far, the only effective method to reduce the mortality is risk-reducing surgery including bilateral salpingo-oophorectomy (rrBSO) <ref type="bibr" target="#b16">[17]</ref>.</s><s>As rrBSO cannot be recommend to the general population, identification of population at risk might help to identify those women in whom the benefit of rrBSO may outweight it's burden.</s><s>Identifying families with deleterious BRCA1/2 variants might provide this opportunity.</s></p><p><s>So far, we did not know how many family members must be affected before we can assume an elevated risk for their relatives and especially, if one affected member already qualifies for genetic testing.</s><s>A further hurdle is the decreasing number of family members in Germany over decades and more recently the increase of so-called blended families.</s><s>In Germany and in most other countries, genetic testing of patients with ovarian cancer is limited to patients with a family history of breast and/or ovarian cancer.</s><s>The aim of this study was to investigate the prevalence of genetic risk factors in consecutive patients with ovarian cancer irrespective of family history and histologic subtype treated in centers of the Arbeitsgemeinschaft Gyna ¨kologische Onkologie (AGO) study group.</s><s>In addition, we wanted to evaluate patient satisfaction with gynecological oncology counseling.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>The protocol was approved by the ethical committee of the Landesaerztekammer Nordrhein (Nr.</s><s>2014340) and registered (NCT02222883); all patients gave written informed consent prior to any study related procedure.</s><s>Patients aged at least 18 years with primary diagnosis or platinum-sensitive relapse of invasive epithelial ovarian cancer in Germany were tested and counselled in 20 centers of the AGO study group in Germany.</s><s>Platinum sensitive disease was defined as relapse at least 6 months after prior platinum based chemotherapy.</s><s>It was allowed to include patients up to 6 months after last platinum dose and patients with more than one prior platinum line.</s><s>We excluded patients with non-epithelial ovarian malignancy and those with a platinum-free interval of less than 6 months.</s><s>Demographic data, disease characteristics, family history, and medical history were documented.</s><s>Further follow up of the patients is planned for 5 years and will be reported later.</s><s>A positive family history was defined as at least one relative with breast cancer or ovarian cancer or breast cancer in personal history.</s><s>This means, that also patients with the diagnosis of breast cancer in personal history and now the additional diagnosis of ovarian cancer were classified as having a positive family history.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Gene selection</head><p><s>Germline testing was centrally performed at the Center of Hereditary Breast and Ovarian Cancer at the University of Cologne, Germany.</s><s>Testing included 25 established and candidate risk genes related to ovarian and/or breast cancer or rare cancer predisposition syndromes (ATM, BARD1, BRCA1, BRCA2, BRIP1, BUB1B, CDH1, CHEK1, CHEK2, FAM175A, FANCM, MLH1, MSH2, MSH6, MRE11A, NBN, PMS2, PTEN, PALB2, RAD50, RAD51C, RAD51D, STK11, TP53, XRCC2).</s><s>Among these 25 genes, 16 were defined as as established cancer "risk genes", including the Lynch syndrome-associated genes (MLH1, MSH2, MSH6, PMS2), genes causative for rare cancer predisposition syndromes (CDH1, PTEN, STK11, TP53), and genes known to contribute to hereditary breast and/or ovarian cancer risk, namely ATM, BRCA1, BRCA2, CHEK2, NBN, PALB2, RAD51C and RAD51D <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b21">22]</ref>.</s><s>For the remaining 9 genes, only limited evidence is available so far for BUB1B, BARD1, BRIP1, CHEK1, FANCM, FAM175A, MRE11A, RAD50 and XRCC2 <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28]</ref>.</s><s>BUB1B and CHEK1 were included because deleterious variants in both genes have been described in ovarian cancer patients <ref type="bibr" target="#b28">[29]</ref>.</s><s>We classified the analyzed genes in 3 different categories: BRCA1/BRCA2 (group A), 16 risk genes (group B) and all 25 genes (group C).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genetic analyses</head><p><s>Genomic DNA was isolated from venous blood samples using standard methods.</s><s>All samples were screened for gross genomic aberrations in the BRCA1/2 genes by Multiplex Ligationdependent Probe Amplification (MLPA) using the SALSA 1 MLPA 1 probemixes P002 (BRCA1) and P045 (BRCA2) (MRC-Holland, Amsterdam, The Netherlands) according to the manufacturers protocol.</s><s>Data was analysed using the Coffalyzer.Net v.140429.1057</s><s>software (MRC-Holland).</s><s>All BRCA1/2 deletions/duplications were verified using the SALSA 1 MLPA 1 probemixes P087 (BRCA1) or P077 (BRCA2), respectively (MRC-Holland).</s><s>All samples were subsequently analyzed by next generation sequencing (NGS) covering the entire coding regions and exon-flanking sequences (±15nt) of the 25 above-mentioned genes.</s><s>For NGS, we employed a customer-tailored SureSelect gene panel (Agilent, Santa Clare, U.S.) using the XT Target Enrichment for Illumina Paired-End Multiplexed Sequencing protocol optimized for 200ng of genomic DNA (Agilent).</s><s>Sequencing was performed on MiSeq or HiSeq4000 devices (Illumina, San Diego, U.S.).</s><s>Bioinformatic analyses were carried out using the VAR-BANK version 2.10 pipeline of the Cologne Center for Genomics.</s><s>In addition, the obtained NGS data were utilized to identify LGRs (large genomic rearrangements) in non BRCA1/2 genes using an in silico CNV-Tool incorporated in the Sophia DDM 1 platform (Sophia Genetics).</s><s>Conspicuous regions indicative for a duplication or deletion were verified using an appropriate SALSA 1 MLPA 1 probemix, if available (MRC-Holland) or by aCGH (Array comparative genomic hybridization) using a customized probe set covering the regions of interest (Agilent).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Variant classification</head><p><s>Variant classification was performed in accordance with the regulations of the international ENIGMA consortium (Evidence-based Network for the Interpretation of Germline Mutant Alleles; https://enigmaconsortium.org; version 1.1: 26 th of March 2015).</s><s>All genetic variants were classified using a 5-tier variant classification system as proposed by the International Agency for Research on Cancer (IARC) Unclassified Genetic Variants Working Group, namely, deleterious = class 5, likely deleterious = class 4, variant of uncertain significance (VUS) = class 3, likely benign = class 2, and benign = class 1 <ref type="bibr" target="#b29">[30]</ref>.</s><s>Variants reported to occur in large outbred control reference groups at an allele frequency !1% (MAF !</s><s>0.01) are generally considered to be benign (class 1).</s><s>Class 4/5 variants are subsequently denominated as ´deleterious variants´.</s><s>All deleterious variants were validated by Sanger sequencing.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Counselling</head><p><s>Counselling was performed by gynecologic oncologists according to local standard and we evaluated the patient perspectives and satisfaction regarding testing and counseling by a survey.</s><s>Patients had a BRCA elucidation before testing by their treating gynecologic oncologist and in case of a positive result a subsequent counselling by a gynecologic oncologist or geneticist depending on the local standard.</s><s>The patients were asked the following questions after testing:</s></p><p><s>• Finden Sie es gut, dass Ihnen eine Beratung und Testung bzgl.</s><s>ihres familia ¨ren Risikos angeboten wurde?</s><s>(Did you appreciate that counselling and testing regarding your family risk was offered to you?)</s></p><p><s>• Waren Sie mit der Beratung zufrieden?</s><s>(Were you satisfied with the counselling?)</s></p><p><s>• Waren Sie mit der Ergebnismitteilung zufrieden?</s><s>(Were you satisfied with how the result was communicated?)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical methods</head><p><s>The protocol stated a target sample size of 500 patients.</s><s>No formal power analysis was performed.</s><s>The primary objectives were to assess the prevalence of deleterious germline variants in the investigated genes.</s><s>All analyses are merely descriptive; no confirmatory hypothesis testing was done.</s><s>The prevalence was calculated as number of patients with at least one deleterious variant in the respective genes or gene categories divided by all tested patients.</s><s>SAS version 9.4 was used for all statistical analyses.</s><s>Further details are provided in the study protocol (S1 study protocol and S1 Trend Statement Checklist)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>In total, 525 patients were registered and blood was sent for testing in 523 cases including 281 patients with primary ovarian cancer and 242 with relapsed platinum-sensitive ovarian cancer between 3/2015 and 7/2015 (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The majority of the patients were of White/Caucasian/  ; two-sided chi-square p = 0.1).</s><s>Furthermore, we analyzed the prevalence of deleterious variants by different subgroups regarding age (&lt; versus !</s><s>60 years), family history (positive versus negative) and histologic subtypes (high-grade serous versus others).</s><s>All analyses in all subgroups showed a prevalence of deleterious BRCA1/2 variants above 10.0%.</s><s>The highest prevalence of deleterious BRCA1/2 variants was 30.2% in patients below the age of 60 years at primary diagnosis and 31.6% with a positive family history, respectively.</s><s>Of note, 33/109 patients (30.3%) with deleterious BRCA1/ 2 variants would have been missed by using the classical criteria family history.</s><s>This rate increases to missing 51/138 patients (37%) regarding the 16 risk genes as defined in our series.</s><s>However, the threshold frequency of 10% that qualifies for reimbursement of consultation and testing was observed in every subgroup analyzed and even analysis per decade of patients' age did not identify any subgroup with a lower rate of deleterious variants-unfortunately, we were not able to analyze patients in their octogenarium who are underrepresented in our trial with 11 patients only.</s></p><p><s>The prevalence of deleterious variants in the 16 risk genes ranged from 14.8% (patients with a histologic subtype other than HGS, Table <ref type="table" target="#tab_3">3</ref>) to 36.0%</s><s>(patients with a positive family history, Table <ref type="table" target="#tab_3">3</ref>) and the prevalence of deleterious variants in any of the investigated genes from 16.7 (patients with a histologic subtype other than HGS, Table <ref type="table" target="#tab_3">3</ref>) to 36.4% (patients with a positive family history, Table <ref type="table" target="#tab_3">3</ref>).</s><s>The number of patients with non high-grade serous histologic subtypes was limited, however, deleterious BRCA1/2 variants were also detected in non high grade serous histo-types.</s><s>Twenty-three patients had high-grade endometrioid histology.</s><s>This subtype showed a prevalence of deleterious variants in the BRCA1/2 genes of 13%, 21.7% had a deleterious variant in at least one of the 16 risk genes.</s><s>Furthermore, we had 18 patients with low-grade serous histology (deleterious variant in BRCA1/2: 5.6%, risk gene: 11.1%, any gene: 16.7%).</s><s>All other known histologic subtypes included less than 10 patients (Table <ref type="table" target="#tab_4">4</ref>).</s><s>The rate of deleterious variants in the Lynch-associated genes (MSH2, MSH6, MLH1, PMS2) was 0.6% (3 patients; 2 MSH2-positive patients, 1 with high grade serous and 1 with high-grade endometrial subtype; 1 MSH6-positive patient with high-grade serous subtype).</s><s>The compliance with the survey was high and the rate of responders for each of the questions was 80.9% each ("Did you appreciate that counselling and testing regarding your family risk was offered to you?" and "Were you satisfied with the counselling?")</s><s>and 66.2% ("Were you satisfied with how the result was communicated?").</s><s>Question 1 (Did you appreciate that counselling and testing regarding your family risk was offered to you?) was answered with "yes" by 98.4%, question 2 (Were you satisfied with the counselling?)</s><s>by 93.9% and question 3 (Were you satisfied with how the result was communicated?) by 97.4% of the participating patients.</s><s>The corresponding rates for "No" were 0.5%, 3.2%, and 1.2%, respectively.</s><s>The rates of "I don't know" were 1.2%, 2.9% and 1.2%, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Our data indicate that a genetic background regarding the development of ovarian cancer is present in a higher proportion of patients than anticipated in the past.</s><s>The strength of our trial is the testing of consecutive unselected patients with ovarian cancer in a multicenter setting.</s><s>The rate of patients with deleterious variants in BRCA1/2 was about 21% without any meaningful difference between patients with first diagnosis or relapsed disease.</s><s>This is in line with other recent publications reporting a rate of BRCA1/2 carriers of about <ref type="bibr">16-19% [23, 31,32]</ref>.</s><s>One of the main questions for the future is therefore, how we could prevent about 1/5 of all ovarian cancer cases.</s><s>According to the National Institute for Health and Care Excellence (NICE), genetic BRCA1/2 testing is generally recommended when the combined probability to detect a deleterious BRCA1 and BRCA2 variant is !</s><s>10% <ref type="bibr" target="#b26">[27]</ref>.</s><s>Thus, age at onset and family history were the main selection criteria to identify suitable index patients for genetic testing to identify families at risk.</s><s>However, this resulted in multiple different guidelines regarding selection criteria differing between the countries and medical societies <ref type="bibr" target="#b32">[33]</ref>.</s><s>Family history and age at onset are only of limited value to identify patients at genetic risk.</s><s>This was already reported by other authors <ref type="bibr" target="#b34">[34,</ref><ref type="bibr" target="#b35">35,</ref><ref type="bibr" target="#b36">36,</ref><ref type="bibr" target="#b37">37,</ref><ref type="bibr" target="#b38">38]</ref>.</s><s>Using traditional criteria might miss about one third of all patients with a hereditary risk regarding BRCA1/2.</s><s>In our cohort, 33/109 patients (30.28%) with deleterious variants in BRCA1/2 would have been missed by using only classical criteria like family history.</s><s>This rate increases to missing 51/138 patients (37%) regarding the 16 risk genes as defined in our series.</s><s>Disease modifiers that are independent from BRCA1/2, de novo mutations, or limited family structures may explain the finding that a subgroup of BRCA1/2positive patients with ovarian cancer did not show a positive family history.</s></p><p><s>A limitation of our series is the limited number of patients with other histologic subtypes than high-grade serous ovarian cancer.</s><s>Unfortunately, we have only less than 10 patients with a mucinous or clear cell histologic subtype.</s><s>Therefore, we are not able to give an appropriate answer regarding the rate of deleterious variants in this subtype.</s><s>Of note, we reported already the finding of deleterious BRCA1/2 variants in patients with clear cell and mucinous ovarian cancer within an international multicenter first line therapy trial <ref type="bibr" target="#b30">[31]</ref>.</s><s>Whether this finding was by chance or revealed indeed the driver alterations for ovarian cancers remains an open question.</s><s>In addition, the changed classification of the histologic subtypes in ovarian cancer in 2014 has to be kept in mind as further potential factor.</s><s>Within a large multicenter study, it was shown that reviewing the pathologic samples by an expert gynecologic pathologist using the old and new classification system results in diagnosing the same histologic subtype again in only 54% <ref type="bibr" target="#b39">[39]</ref>.</s><s>In accordance to another recent presentation, we could also show that gynecologic oncologist led testing shows a high level of satisfaction in patients with ovarian cancer <ref type="bibr" target="#b40">[40]</ref>.</s></p><p><s>In conclusion, the limited value of any supporting instruments to identify families at risk of ovarian cancer highlights the necessity to offer germline testing to all patients with ovarian cancer.</s><s>This is so far the only option we have, to identify families at risk for the usually fatal course of the disease of ovarian cancer.</s><s>Offering prophylactic surgery in BRCA1/2-positive women is the only effective option to decrease ovarian cancer mortality.</s><s>Therefore, Scotland established offering genetic testing to all patients with non-mucinous histologies of ovarian cancer already in 2013 <ref type="bibr" target="#b41">[41]</ref>.</s><s>The results of our study were already discussed with German health care providers and the Medizinische Dienst der Krankenkassen (MDK), which led to offering testing to all patients with ovarian cancer up to the age of 80 years who were covered by the Verband der Ersatzkassen in Germany in October 2016.</s><s>Negotiations with further health care providers are ongoing.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . Patient characteristics. Variable All (n = 523)</head><label>1</label><figDesc><div><p><s>European heritage (96.8%) followed by White/Arabic/North African heritage with 1.3%.Other ethnicities were more infrequent (&lt; 0.5%).The mean age at primary diagnosis of all patients was 58 years, 43% had a positive family history and 77.6% showed a high-grade serous ovarian cancer (Table1).In total, 146 of 523 patients (27.9%) showed a deleterious variant in at least one of the investigated genes (S1 Table), of which 9 patients carried two deleterious germline variants (S2 Table).In the overall sample, 109 patients carried a deleterious variant in BRCA1, BRCA2, or both genes (Table2, S1 and S2 Tables).</s><s>In this subgroub of 109 patients with deleterious BRCA1/2 variants, 6 carried deleterious variants in further genes investigated in this study (</s></p></div></figDesc><table><row><cell>Age (mean, range) [years]</cell><cell>58 (16-93)</cell></row><row><cell>Positive family history (%)</cell><cell>225 (43.0)</cell></row><row><cell>Histologic subtype (%)</cell><cell></cell></row><row><cell>High grade serous</cell><cell>406 (77.6)</cell></row><row><cell>High grade endometrioid</cell><cell>23 (4.4)</cell></row><row><cell>Low grade serous</cell><cell>18 (3.4)</cell></row><row><cell>Low grade endometrioid</cell><cell>7 (1.3)</cell></row><row><cell>Clear cell</cell><cell>6 (1.1)</cell></row><row><cell>Mucinous</cell><cell>9 (1.7)</cell></row><row><cell>Others/unspecified</cell><cell>45 (8.6)</cell></row><row><cell>Missing</cell><cell>9 (1.7)</cell></row><row><cell>Timepoint of inclusion</cell><cell></cell></row><row><cell>Primary ovarian cancer</cell><cell>281 (53.7)</cell></row><row><cell>Recurrent ovarian cancer</cell><cell>242 (46.3)</cell></row></table><note><p><s>https://doi.org/10.1371/journal.pone.0186043.t001</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc></figDesc><table><row><cell>). Deleterious germline variants in BRCA1 were most abundant (81 patients,</cell></row><row><cell>15.5%), followed by BRCA2 (29 patients, 5.5%), RAD51C (13 patients, 2.5%) and PALB2 (6</cell></row></table><note><p><s>patients, 1.1%).Deleterious variants in all other genes analyzed were identified in less than 1% of the patients each (Table2).</s><s>The combined analysis showed the following prevalence of deleterious veriants for the respective categories: BRCA1/2: 20.8% (group A, 109 patients); risk genes: 26.4% (group B, 138 patients); all genes: 27.9% (group C, 146 patients).</s><s>The number of</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 . Prevalence of deleterious variants in the selected genes</head><label>2</label><figDesc></figDesc><table><row><cell>BRCA1/2 (group A)</cell></row></table><note><p><s>. No deleterious variants were observed in BARD1, CDH1, MLH1, PMS2, PTEN, STK11 and TP53.</s><s>Genes / gene categories Patients, (% of all; n = 523) https://doi.org/10.1371/journal.pone.0186043.t002</s><s>patients with at least one deleterious vatiant in any gene (group C) was slightly though not statistically significantly higher in the relapsed versus the primary diagnosis cohort (21.4% [76 of 242] versus 24.9% [70 of 281]</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 . Prevalence of deleterious variants within subgroups.</head><label>3</label><figDesc></figDesc><table><row><cell>Subgroup</cell><cell>n</cell><cell>BRCA1/2 positive</cell><cell>risk genes</cell><cell>any gene</cell></row><row><cell></cell><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>All (%)</cell><cell>523</cell><cell>109 (20.8)</cell><cell>138 (26.4)</cell><cell>146 (27.9)</cell></row><row><cell>Age*</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt; 60 years</cell><cell>268</cell><cell>81 (30.2)</cell><cell>89 (33.2)</cell><cell>94 (35.1)</cell></row><row><cell>! 60 years</cell><cell>254</cell><cell>27 (10.6)</cell><cell>48 (18.9)</cell><cell>51 (20.1)</cell></row><row><cell>Family history</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Positive</cell><cell>225</cell><cell>71 (31.6)</cell><cell>81 (36.0)</cell><cell>82 (36.4)</cell></row><row><cell>Negative</cell><cell>289</cell><cell>33 (11.4)</cell><cell>51 (17.6)</cell><cell>58 (20.1)</cell></row><row><cell>Histologic subtype*</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>High grade serous (HGS)</cell><cell>406</cell><cell>94 (23.2)</cell><cell>118 (29.1)</cell><cell>123 (30.3)</cell></row><row><cell>other</cell><cell>108</cell><cell>11 (10.2)</cell><cell>16 (14.8)</cell><cell>18 (16.7)</cell></row><row><cell>Within subset of HGS</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Primary diagnosis</cell><cell>203</cell><cell>46 (22.7)</cell><cell>54 (26.6)</cell><cell>57 (28.1)</cell></row><row><cell>Relapse</cell><cell>203</cell><cell>48 (23.6)</cell><cell>64 (31.5)</cell><cell>66 (32.5)</cell></row></table><note><p><s>* Age class was missing for 1 patient; histologic subtype was missing for 9 patients.</s><s>https://doi.org/10.1371/journal.pone.0186043.t003</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 4 . Histologic subtypes and prevalence of deleterious variants in patients with serous, endometrioid, mucinous or clear cell ovarian cancer.</head><label>4</label><figDesc></figDesc><table><row><cell>Histologic subtype</cell><cell>n</cell><cell>BRCA1/2 positive</cell><cell>risk gene positive</cell><cell>any gene</cell></row><row><cell></cell><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>High grade serous</cell><cell>406</cell><cell>94 (23.2)</cell><cell>118 (29.1)</cell><cell>123 (30.3)</cell></row><row><cell>Low grade serous</cell><cell>18</cell><cell>1 (5.6)</cell><cell>2 (11.1)</cell><cell>3 (16.7)</cell></row><row><cell>High grade endometrioid</cell><cell>23</cell><cell>3 (13.0)</cell><cell>5 (21.7)</cell><cell>5 (21.7)</cell></row><row><cell>Low grade endometrioid</cell><cell>7</cell><cell>1 (14.3)</cell><cell>1 (14.3)</cell><cell>1 (14.3)</cell></row><row><cell>Mucinous</cell><cell>9</cell><cell>0</cell><cell>0</cell><cell>1 (11.11)</cell></row><row><cell>Clear cell</cell><cell>6</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>https://doi.org/10.1371/journal.pone.0186043.t004</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>S1 Table. Deleterious heterozygous germline variants. (DOCX) S2 Table. Patients carrying two deleterious variants.</head><label></label><figDesc></figDesc><table><row><cell>S1 Study protocol.</cell></row><row><cell>(PDF)</cell></row><row><cell>S1 Trend Statement Checklist.</cell></row><row><cell>(PDF)</cell></row></table><note><p><s>(DOCX)</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | https://doi.org/10.1371/journal.pone.0186043October 20, 2017  </note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We would like to thank Astra Zeneca Germany for the support of the trial, the team of Peter Schantl (Schantl Pharmacy Service, Wiesbaden, Germany) for the monitoring, the team of Carmen Schade-Brittinger (Coordinating Center for Clinical trials, University of Marburg, Marburg, Germany) for the statistical analysis and the team of Gabriele Elser (AGO Study Group, Wiesbaden/Essen, Germany) for data management.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Contributions</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EURO-CARE-5 study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chirlaque</forename><surname>Lopez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Agresti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sanche ´z Pe ´rez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Holleczeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Bielska</forename><surname>Lasota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<date type="published" when="2015-09-06">2015 Sep 6</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Cancer statistics</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="271" to="289" />
			<date type="published" when="2016-07">2016. 2016 Jul</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lu ¨ck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mo ¨bus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Costa</surname></persName>
		</author>
		<idno type="PMID">12953086</idno>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="1320" to="1329" />
			<date type="published" when="2003-09-03">2003 Sep 3</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Bevacizumab in the treatment of ovarian cancer</title>
		<author>
			<persName><forename type="first">F</forename><surname>Heitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Harter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Barinoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Beutel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kannisto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Grabowski</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12325-012-0041-9</idno>
		<idno type="PMID">22941523</idno>
		<ptr target="https://doi.org/10.1007/" />
	</analytic>
	<monogr>
		<title level="j">Adv Ther</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="723" to="735" />
			<date type="published" when="2012-09">2012 Sep</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Hanker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Burchardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pfisterer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pujade-Lauraine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2065" to="2077" />
			<date type="published" when="2012-10">2012 Oct</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Impact of a structured quality management program on surgical outcome in primary advanced ovrian cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Harter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">M</forename><surname>Muallem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Buhrmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lorenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kaub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hils</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2011.02.014</idno>
		<idno type="PMID">21414656</idno>
		<ptr target="https://doi.org/10.1016/j.ygyno.2011.02.014" />
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="615" to="619" />
			<date type="published" when="2011-06-01">2011 Jun 1</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Harter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hahmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hasenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Burges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
		<idno type="DOI">10.1245/s10434-006-9058-0</idno>
		<idno type="PMID">17009163</idno>
		<ptr target="https://doi.org/10.1245/s10434-006-9058-0" />
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1702" to="1710" />
			<date type="published" when="2006-12">2006 Dec</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Contribution of BRCA 1 mutations to ovarian cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Stratton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Gayther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dearden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Plake</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJM199704173361602</idno>
		<idno type="PMID">9099656</idno>
		<ptr target="https://doi.org/10.1056/NEJM199704173361602" />
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">336</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="1125" to="1130" />
			<date type="published" when="1997-04-17">1997 Apr 17</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Risch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mclaughlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Cole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bradley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kwan</surname></persName>
		</author>
		<idno type="DOI">10.1086/318787</idno>
		<idno type="PMID">11179017</idno>
		<ptr target="https://doi.org/10.1086/318787" />
	</analytic>
	<monogr>
		<title level="j">Am J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="700" to="710" />
			<date type="published" when="2001-03">2001 Mar</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies</title>
		<author>
			<persName><forename type="first">A</forename><surname>Antoniou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Pharoah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Narod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Risch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Eyfjord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hopper</surname></persName>
		</author>
		<idno type="DOI">10.1086/375033</idno>
		<idno type="PMID">12677558</idno>
		<ptr target="https://doi.org/10.1086/375033" />
	</analytic>
	<monogr>
		<title level="j">Am J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1117" to="1130" />
			<date type="published" when="2003-05">2003 May</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">New York Breast Cancer Study G: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Marks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Mandell</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.1088759</idno>
		<idno type="PMID">14576434</idno>
		<ptr target="https://doi.org/10.1126/science.1088759" />
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">302</biblScope>
			<biblScope unit="issue">5645</biblScope>
			<biblScope unit="page" from="643" to="646" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Antoniou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Peto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lalloo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Narod</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.bjc.6604305</idno>
		<idno type="PMID">18349832</idno>
		<ptr target="https://doi.org/10.1038/sj.bjc.6604305" />
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1457" to="1466" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE</title>
		<author>
			<persName><forename type="first">N</forename><surname>Mavaddat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Peock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Frost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Platte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fineberg</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djt095</idno>
		<idno type="PMID">23628597</idno>
		<ptr target="https://doi.org/10.1093/jnci/djt095" />
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="812" to="822" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovaran (PLCO) Cancer Screening Randomized Controlled Trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Buys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Partridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lamerato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Isaacs</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2011.766</idno>
		<idno type="PMID">21642681</idno>
		<ptr target="https://doi.org/10.1001/jama.2011.766" />
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2295" to="2303" />
			<date type="published" when="2011-06-08">2011 Jun 8</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Ovarian tumorgenesis: a proposed model based on morphological and molecular genetic analysis</title>
		<author>
			<persName><surname>Shih Lem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Kurman</surname></persName>
		</author>
		<idno type="PMID">15111296</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1511" to="1518" />
			<date type="published" when="2004-05">2004 May</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Serous Tubal Intraepithelial Cacrinoma Associated With Extraovarian Metastases</title>
		<author>
			<persName><forename type="first">S</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Heikaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Harter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Heitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grimm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ataseven</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Geynecol Cancer</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="444" to="451" />
			<date type="published" when="2017-03">2017 Mar</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1or 2 mutation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Mu ¨ller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Danner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rhiem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Stollenwerk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rasche</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10198-017-0887-5</idno>
		<idno type="PMID">28382503</idno>
		<ptr target="https://doi.org/10.1007/s10198-017-0887-5" />
	</analytic>
	<monogr>
		<title level="j">Eur J Health Econ</title>
		<imprint>
			<date type="published" when="2017-04-05">2017 Apr 5</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Easton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Pharoah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Antoniou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tischkowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Tavtigian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Nathanson</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMsr1501341</idno>
		<idno type="PMID">26014596</idno>
		<ptr target="https://doi.org/10.1056/NEJMsr1501341" />
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2243" to="2257" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Walsh</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2015.02.017</idno>
		<idno type="PMID">25725131</idno>
		<ptr target="https://doi.org/10.1016/j.ygyno.2015.02.017" />
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="343" to="350" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene</title>
		<author>
			<persName><forename type="first">A</forename><surname>Meindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hellebrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wiek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Erven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wappenschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Niederacher</surname></persName>
		</author>
		<idno type="DOI">10.1038/ng.569</idno>
		<idno type="PMID">20400964</idno>
		<ptr target="https://doi.org/10.1038/ng.569" />
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="410" to="414" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Ramus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Tyrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Rosenthal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Intermaggio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">11</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Kiiski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Pelttari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Freysteinsdottir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Reynisdottir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Hart</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.1407909111</idno>
		<idno type="PMID">25288723</idno>
		<ptr target="https://doi.org/10.1073/pnas.1407909111" />
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">42</biblScope>
			<biblScope unit="page" from="15172" to="15177" />
			<date type="published" when="2014-10-21">Oct 21 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Easton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Pharoah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Antoniou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tischkowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Tavtigian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Nathanson</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMsr1501341</idno>
		<idno type="PMID">26014596</idno>
		<ptr target="https://doi.org/10.1056/NEJMsr1501341" />
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2243" to="2257" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Walsh</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2015.02.017</idno>
		<idno type="PMID">25725131</idno>
		<ptr target="https://doi.org/10.1016/j.ygyno.2015.02.017" />
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="343" to="350" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene</title>
		<author>
			<persName><forename type="first">A</forename><surname>Meindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hellebrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wiek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Erven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wappenschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Niederacher</surname></persName>
		</author>
		<idno type="DOI">10.1038/ng.569</idno>
		<idno type="PMID">20400964</idno>
		<ptr target="https://doi.org/10.1038/ng.569" />
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="410" to="414" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Ramus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Tyrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Rosenthal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Intermaggio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">11</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Kiiski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Pelttari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Freysteinsdottir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Reynisdottir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Hart</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.1407909111</idno>
		<idno type="PMID">25288723</idno>
		<ptr target="https://doi.org/10.1073/pnas.1407909111" />
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">42</biblScope>
			<biblScope unit="page" from="15172" to="15177" />
			<date type="published" when="2014-10-21">Oct 21 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Inherited mutations in woman with ovarian carcinoma</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Norquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Harrel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gulsuner</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamaoncol.2015.5495</idno>
		<idno type="PMID">26720728</idno>
		<ptr target="https://doi.org/10.1001/jamaoncol.2015.5495" />
	</analytic>
	<monogr>
		<title level="j">JAMA Oncol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="482" to="490" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Pennington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Harrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Pennil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Rendi</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-13-2287</idno>
		<idno type="PMID">24240112</idno>
		<ptr target="https://doi.org/10.1158/1078-0432.CCR-13-2287" />
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="764" to="775" />
			<date type="published" when="2014-02-01">2014 Feb 1</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Plon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Eccles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Easton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Foulkes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Genuardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Greenblatt</surname></persName>
		</author>
		<idno type="DOI">10.1002/humu.20880</idno>
		<idno type="PMID">18951446</idno>
		<ptr target="https://doi.org/10.1002/humu.20880" />
	</analytic>
	<monogr>
		<title level="j">Hum Mutat</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1282" to="1291" />
			<date type="published" when="2008-11">2008 Nov</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil</title>
		<author>
			<persName><forename type="first">S</forename><surname>Maistro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Encinas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Katayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Niewiadonski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Cabral</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12885-016-2966-x</idno>
		<idno type="PMID">27914478</idno>
		<ptr target="https://doi.org/10.1186/s12885-016-2966-x" />
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">934</biblScope>
			<date type="published" when="2016-12-03">2016 Dec 3</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Konstantinopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ceccaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Shapiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'andrea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.CD-15-0714</idno>
		<idno type="PMID">26463832</idno>
		<ptr target="https://doi.org/10.1158/2159-8290.CD-15-0714" />
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1137" to="1154" />
			<date type="published" when="2015-11">2015 Nov</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Eccles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Balmaña</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Clune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ehlken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gohlke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hirst</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title/>
		<idno type="DOI">10.1007/s12325-016-0281-1</idno>
		<idno type="PMID">26809252</idno>
		<ptr target="https://doi.org/10.1007/s12325-016-0281-1" />
	</analytic>
	<monogr>
		<title level="j">Adv Ther</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="129" to="150" />
			<date type="published" when="2016-02">2016 Feb</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing</title>
		<author>
			<persName><forename type="first">T</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Casadei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Pennil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Nord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Thornton</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.1115052108</idno>
		<idno type="PMID">22006311</idno>
		<ptr target="https://doi.org/10.1073/pnas.1115052108" />
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="18032" to="18037" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark</title>
		<author>
			<persName><forename type="first">M</forename><surname>Soegaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Kjaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wozniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Høgdall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Høgdall</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-07-4806</idno>
		<idno type="PMID">18559594</idno>
		<ptr target="https://doi.org/10.1158/1078-0432.CCR-07-4806" />
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="3761" to="3767" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden</title>
		<author>
			<persName><forename type="first">S</forename><surname>Malander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ridderheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Måsba ¨ck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Loman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kristoffersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Olsson</surname></persName>
		</author>
		<idno type="PMID">14746861</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="422" to="428" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group</title>
		<author>
			<persName><forename type="first">K</forename><surname>Alsop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fereday</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meldrum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Defazio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Emmanuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>George</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2011.39.8545</idno>
		<idno type="PMID">22711857</idno>
		<ptr target="https://doi.org/10.1200/JCO.2011.39.8545" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="2654" to="2663" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study</title>
		<author>
			<persName><forename type="first">P</forename><surname>Harter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Berton-Rigaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Friedlander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Campo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2015.12.027</idno>
		<idno type="PMID">26740259</idno>
		<ptr target="https://doi.org/10.1016/j.ygyno.2015.12.027" />
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="443" to="449" />
			<date type="published" when="2016-03">2016 Mar</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Ovarian carcinoma diagnosis: the clinical impact of 15 years of change</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kommoss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Gilks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kommoss</surname></persName>
		</author>
		<idno type="DOI">10.1038/bjc.2016.273</idno>
		<idno type="PMID">27632374</idno>
		<ptr target="https://doi.org/10.1038/bjc.2016.273" />
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="993" to="999" />
			<date type="published" when="2016-10-11">2016 Oct 11</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">A novel oncologist-lead BRCA1/2 germline mutation (gBRCAm) testing and counselling model for patients with ovarian cancer: Interim results from the ENGAGE (NCT02406235) study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Scambia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chalas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grana</forename><surname>Suarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Gonza</forename><surname>´lez-Santiago</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Colombo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Presented at Annual Meeting of the European Society of Medical Oncologist 2016 # LBA34</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Scottish Intercollegiate Guidelines Network (SIGN)</title>
	</analytic>
	<monogr>
		<title level="j">Edinburgh: SIGN</title>
		<imprint>
			<biblScope unit="issue">135</biblScope>
			<date type="published" when="2013-11">2013. November 2013</date>
		</imprint>
	</monogr>
	<note>Management of epithelial ovarian cancer</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
